Thymalin
Low EvidenceA thymic peptide preparation studied for immune system rejuvenation and age-related immune decline.
What It Is
Thymalin (also known as thymic factor extract or thymalin dipeptide) is a polypeptide complex originally isolated from calf thymus glands, developed at the Khavinson Institute of Bioregulation and Gerontology in Russia. It belongs to the bioregulatory peptide class and is proposed to support thymic function, immune reconstitution, and immunosenescence reversal. Thymalin has been used clinically in Russia and several CIS countries since the 1980s as an immunomodulator for conditions including post-surgical immunosuppression, chronic infections, and age-related immune decline. A notable 2003 study by Khavinson and Morozov reported that long-term thymalin administration (combined with epithalamin) in elderly patients was associated with reduced cardiovascular mortality over a 6-year follow-up period, though the study had significant methodological limitations including small sample size and lack of rigorous blinding. The active components of thymalin preparations are not fully characterized to Western pharmaceutical standards, and the bioregulatory peptide theory underlying its development — that short peptide sequences can directly interact with gene promoters — remains unvalidated by independent research groups. Thymalin is not available in the United States or European Union as a pharmaceutical product. It should not be confused with Thymosin Alpha-1 (Zadaxin), which is a distinct, well-characterized 28-amino acid peptide with a robust clinical evidence base.
Why Researchers Study It
Thymalin is part of a class of bioregulatory peptides developed by Khavinson and colleagues in Russia, based on the theory that short tissue-specific peptides can restore age-related functional decline in their organ of origin. Its thymic origin positions it as a candidate for studying immune reconstitution in aging populations.
Proposed Mechanisms
- Promotes thymic function and T-cell maturation in aging immune systems
- May normalize CD4/CD8 T-cell ratios in immunosenescent individuals
- Proposed epigenetic regulation of immune-related gene expression
- Part of the Khavinson peptide bioregulation framework alongside Epithalon and Pinealon
Evidence Snapshot
Commonly Discussed Benefits
Safety & Cautions
- Most research published in Russian-language literature
- Limited independent Western validation
- Not FDA-approved
- Quality and standardization may vary between sources
Comparisons
See how Thymalin compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Khavinson VK. — Peptides and ageing. Neuroendocrinol Lett. 2002 PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
Epithalon
Low EvidenceA tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.
Thymosin Alpha-1
High EvidenceA thymic peptide approved in some countries for immune modulation, studied for viral infections and cancer adjunct therapy.
Pinealon
Low EvidenceA short bioregulatory peptide studied for neuroprotective effects and cognitive support in aging.